Back to results
US 2025/0367123 A1Published application
Pulsatile drug delivery system for treating morning akinesia
AssigneeContera Pharma A/S
InventorsJohn Bondo HANSEN, Mikael Søndergård THOMSEN, Ann FULLERTON, Bent HØJGAARD, Peter Gudmund NIELSEN
Life of this patent
Estimating the term…
Abstract
Provided herewith is a pharmaceutical composition comprising, separately or together, a pulsatile release component comprising levodopa and a DOPA decarboxylase inhibitor for the management of OFF-time episodes in patients with Parkinson's disease.
Claims19
A method of treating a motor symptom in a patient in need of treatment thereof comprising orally administering to the patient, 0 to 4 hours prior to bedtime, a pharmaceutical composition consisting of
- an amount of levodopa sufficient for treating the motor symptom;
- an amount of a DOPA decarboxylase inhibitor;
- and
- one or more excipients;
- wherein
- the amount of levodopa sufficient for treating the motor symptom is released from the pharmaceutical composition in one pulsatile release, after a levodopa lag time of at least 3 hours after the oral administration;
- the amount of the DOPA decarboxylase inhibitor is released form the pharmaceutical composition in one pulsatile release after a DOPA decarboxylase inhibitor lag time of at least 3 hours after the oral administration,
- wherein the pharmaceutical composition does not include an amount of controlled release levodopa and wherein the pharmaceutical composition does not include an amount of immediate-release levodopa.
5 more elements
Dependencies are inferred from the claim text.